Moleculin Biotech Ownership
| MBRX Stock | USD 2.73 0.10 3.53% |
Shares in Circulation | First Issued 2015-09-30 | Previous Quarter 2.5 M | Current Value 3.7 M | Avarage Shares Outstanding 8.6 M | Quarterly Volatility 9.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Moleculin |
Moleculin Stock Ownership Analysis
About 15.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.1. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moleculin Biotech recorded a loss per share of 12.04. The entity last dividend was issued on the 1st of February 2021. The firm had 1:15 split on the 22nd of March 2024. Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To find out more about Moleculin Biotech contact the company at (713) 300-5160 or learn more at https://moleculin.com.Besides selling stocks to institutional investors, Moleculin Biotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Moleculin Biotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Moleculin Biotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Moleculin Biotech Quarterly Liabilities And Stockholders Equity |
|
Moleculin Biotech Insider Trades History
Roughly 3.0% of Moleculin Biotech are currently held by insiders. Unlike Moleculin Biotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Moleculin Biotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Moleculin Biotech's insider trades
Moleculin Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Moleculin Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Moleculin Biotech backward and forwards among themselves. Moleculin Biotech's institutional investor refers to the entity that pools money to purchase Moleculin Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sandy Spring Bank | 2024-06-30 | 89.0 | Cva Family Office, Llc | 2024-09-30 | 34.0 | Bank Of America Corp | 2024-06-30 | 28.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 23.0 | North Star Investment Management Corp | 2024-09-30 | 17.0 | Royal Bank Of Canada | 2024-06-30 | 10.0 | Jpmorgan Chase & Co | 2024-06-30 | 6.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Goss Wealth Management Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 156 K | Vanguard Group Inc | 2024-09-30 | 71.4 K |
Moleculin Biotech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moleculin Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moleculin Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moleculin Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Moleculin Biotech Outstanding Bonds
Moleculin Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Moleculin Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Moleculin bonds can be classified according to their maturity, which is the date when Moleculin Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US60855RAL42 Corp BondUS60855RAL42 | View | |
| Molina Healthcare 4375 Corp BondUS60855RAJ95 | View | |
| US60855RAK68 Corp BondUS60855RAK68 | View |
Moleculin Biotech Corporate Filings
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 6th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 13th of September 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.